Literature DB >> 12106000

Clinical use of cholinomimetic agents: a review.

Philip J Blount1, Conner D Nguyen, James T McDeavitt.   

Abstract

BACKGROUND: There are many agents in clinical use that manipulate central nervous system levels of epinephrine, dopamine, and serotonin. However, development of pharmacological options to manipulate central acetylcholine systems has lagged behind because of poor penetration of the blood-brain barrier and significant peripheral nervous system side effects. Newer agents have demonstrated some efficacy in the management of behavioral and cognitive side effects in Alzheimer's disease, and preliminary data in traumatic brain injury suggest acetylcholine esterase inhibitors may play a significant role in the treatment of this patient population as well.
CONCLUSIONS: In this article, the basic neuroanatomy and pharmacology of the central acetylcholine system are reviewed, along with agents currently available for clinical use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106000     DOI: 10.1097/00001199-200208000-00005

Source DB:  PubMed          Journal:  J Head Trauma Rehabil        ISSN: 0885-9701            Impact factor:   2.710


  10 in total

Review 1.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

2.  Citicoline in severe traumatic brain injury: indications for improved outcome : A retrospective matched pair analysis from 14 Austrian trauma centers.

Authors:  Helmut Trimmel; Marek Majdan; Andrea Wodak; Guenther Herzer; Daniel Csomor; Alexandra Brazinova
Journal:  Wien Klin Wochenschr       Date:  2017-07-27       Impact factor: 1.704

3.  An acetylcholinesterase inhibitor, eserine, induces long-term depression at CA3-CA1 synapses in the hippocampus of adult rats.

Authors:  Robert Alan Mans; Brian A Warmus; Caroline C Smith; Lori L McMahon
Journal:  J Neurophysiol       Date:  2014-08-20       Impact factor: 2.714

4.  Central acetylcholinesterase inhibition improves hemodynamic counterregulation to severe blood loss in alcohol-intoxicated rats.

Authors:  Keisa W Mathis; Patricia E Molina
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-06-10       Impact factor: 3.619

Review 5.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

6.  BPSD following traumatic brain injury.

Authors:  Renato Anghinah; Fabio Rios Freire; Fernanda Coelho; Juliana Rhein Lacerda; Magali Taino Schmidt; Vanessa Tomé Gonçalves Calado; Jéssica Natuline Ianof; Sergio Machado; Bruna Velasques; Pedro Ribeiro; Luis Fernando Hindi Basile; Wellingson Silva Paiva; Robson Luis Amorim
Journal:  Dement Neuropsychol       Date:  2013 Jul-Sep

7.  Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1.

Authors:  Jerzy Krupinski; Manal Abudawood; Sabine Matou-Nasri; Raid Al-Baradie; Eugen Bogdan Petcu; Carlos Justicia; Anna Planas; Donghui Liu; Norma Rovira; Marta Grau-Slevin; Julio Secades; Mark Slevin
Journal:  Vasc Cell       Date:  2012-12-10

8.  Screening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status Epilepticus.

Authors:  Bryan S Barker; Jay Spampanato; Hilary S McCarren; Melissa Smolik; Cecelia E Jackson; Eden N Hornung; David T Yeung; F Edward Dudek; John H McDonough
Journal:  Neuroscience       Date:  2019-11-26       Impact factor: 3.708

Review 9.  Citicoline (Cognizin) in the treatment of cognitive impairment.

Authors:  Mario Fioravanti; Ann E Buckley
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

10.  Rivastigmine in the treatment of patients with Alzheimer's disease.

Authors:  Thomas Müller
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.